Concurrent neoadjuvant endocrine therapy with chemotherapy in HR+HER2- breast cancer: a systematic review and meta-analysis.

Front Endocrinol (Lausanne) · 2024 · PMC10933120 · PMID 38481446

Europe PMC DOI

hedged sentence

0.0610

closest p · 1.2× alpha

0.0610

boldest claim

The sentences

did not achieve significancep=0.061so close (0.05 < p ≤ 0.1)

The adjusted HRs preferred sequential over concurrent but did not achieve significance for DFS (HR 0.84, 0.70–1.01, p=0.061) or OS (HR 0.90, 0.73–1.10, p=0.30).

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.